One Percent Rule Checklist For Safer Forex Trading Risk 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
BASKING RIDGE, N.J., April 10, 2017 -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company with a select therapeutic development pipeline focused on immune modulation, announces today that the Company’s 2017 annual stockholder meeting will be held on Tuesday, May 16, 2017 at 11:00 a.m., Eastern Daylight Savings Time, at Hotel Indigo Basking Ridge, 80 Allen Road, Basking Ridge, NJ 07920.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company is investigating its lead product candidate, CLBS03, for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. The Company’s subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy industry and has served over 100 clients since 1999. For more information on Caladrius please visit www.caladrius.com.
Contacts: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: [email protected] Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: [email protected]
